Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases - Wikidata - awgldk - TriplyDB

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases

http://www.wikidata.org/entity/Q34208641

about

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens.Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia Options for T-cell based therapies.Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective.High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis.Autologous stem cell transplantation for systemic sclerosis.T10B9 monoclonal antibody: a short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection.Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy.Hematopoietic SCT for the treatment of multiple sclerosis.A case of pediatric PTLD following autologous stem cell transplantation and review of the literature.Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.Autologous hematopoietic stem cell transplantation in autoimmune diseases.Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases.Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma.Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP.Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation.First autologous hematopoietic SCT for ankylosing spondylitis: a case report and clues to understanding the therapy Translational Research in Stem Cell Treatment of Neuromuscular Diseases

P2860

Q26745838-28138BDD-9400-409A-9772-7EF9138C2D7C Q33884942-2AA8A580-85B3-40B1-BDA5-22C3BD616B6B Q34208618-A9620EE8-000F-4B3A-9FC1-CD267FEA4748 Q34314312-F817FD69-4B83-4A39-8EFC-B7C3403A2E7C Q34622755-DBF45D91-83C4-4166-AF1D-A48DB9BD84AB Q35748459-10DC5844-BE28-4BC7-BFD0-3E404D65E1BE Q35751004-2CF3E535-2F0C-4975-8BAE-5431FBA4A236 Q35813115-D84346EE-F3F1-4FDE-809D-510E0D88254D Q35870515-6A63BF93-2051-45CD-857A-9E4C1B7DFE0F Q35925071-E0D0E590-2FAD-4CA9-B382-BA545E0AA319 Q36020897-8FF98944-7A08-4466-8245-0210C117A543 Q36075481-9AFAD6DD-C411-45FD-91ED-64F18B5C83A0 Q36307574-1507CE90-4EC9-4867-9F3E-0D810B224D33 Q36901406-8B85FDC4-C3A3-41FB-9291-AF1E82A892FF Q37311078-0756197C-379B-4EE6-9026-C528CED54C29 Q37403242-FDFB2956-AD59-44FF-A353-32837FC92204 Q37777360-2E5875A8-DE48-417F-B165-65424C7310E5 Q37778984-2100BBB5-B626-4D68-8B4D-F87C65FED320 Q37785582-E377D7BB-DCA1-49B3-9CD1-567448434B82 Q37793222-A9AFC38D-9F8C-4733-ACD7-821BBBFE579F Q37807871-45B28033-C5AD-4184-900A-6AA40051566C Q37810087-0A42EFBB-AA03-4820-B784-D1DA9F41F2C8 Q37929621-DFDAA806-30E0-46F3-89A6-0B9E04D3C2E9 Q37995011-1DC9E167-BB27-4C0C-BC82-F371CA2FA78D Q39378263-FF4FDBA9-41B0-4C64-9418-5C5E428BFC16 Q40237552-6B91C6F4-0FBD-4CB3-A071-43E90B12AE45 Q42131229-83154796-B104-47CD-A755-9A7693A4B08D Q42154867-8FDCF568-784A-42DE-ACAA-5186CB56AF67 Q42253899-78CE083A-4838-4F29-BC7B-F612B36BF261 Q46301560-06B8B735-462D-4F4B-9C25-A1CEB9841443 Q53641298-62FAF1F4-3889-4907-B7B4-4A3C33B46616 Q58036602-FA21159E-D226-4CB3-A0AB-BDA618439F56 Q59001351-8C366EE5-4B1E-43E5-B74B-AB992F493EF9

P2860

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases

http://www.wikidata.org/entity/Q34208641

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@ast

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@en

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@nl

type

label

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@ast

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@en

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@nl

prefLabel

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@ast

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@en

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@nl

P1433

Q34208641-A16E5DEC-C905-4FF0-8A33-0443D5919E8D

P1476

Q34208641-3B62B2AD-3C4C-4917-92B2-F9E1941DCA71

P2093

Q34208641-20A21D8F-B4E5-4912-865D-A9694EB83586

Q34208641-269A34AC-DA43-451E-822D-B8DE3BDE5F31

Q34208641-3DA5AD45-CDC8-4BBE-BF52-18AA41AADDA0

Q34208641-4EA3F947-9179-42E0-8545-1130C252EF67

Q34208641-60C55B09-3E2C-4995-B99A-A209BCB77F15

Q34208641-639A23EC-8B33-4677-BFE9-6E3B6B5E25F6

Q34208641-6CA500C6-E81F-4856-B6A0-D5A08E86FE88

Q34208641-7BECEC42-6D12-48FD-949E-9FC87B649872

Q34208641-8A8E5EEA-0B03-4F52-B7D5-53CCDE77674B

Q34208641-8F8D9AF0-2C84-433C-B5D8-AFD9BE16032F

P2860

Q34208641-04064574-90D2-4F98-BAF7-501FEB90A5D5

Q34208641-131585BA-62CB-431B-967A-3A1B748E5865

Q34208641-20D4D468-1CB1-4C91-917C-BE2AEAC4D130

Q34208641-237B848A-B571-418C-BC94-169C6B45EA18

Q34208641-284B42B2-F941-4FC8-A5F8-0889D499F339

Q34208641-2AD4754E-DCFC-4E7C-A6EC-B3DDF78E62E8

Q34208641-2B1313BA-8D9D-43BD-ABBA-FAB49297EBA0

Q34208641-2CBC4265-D33A-491E-B2FE-DAABB935AD76

Q34208641-3F7F992F-B743-4CBD-8183-1A1F19C79547

Q34208641-486C0580-13C3-46D8-A8A3-9125B72487DA

P304

Q34208641-63260C16-E515-43A8-B883-12F15AC3EBD5

P31

Q34208641-72A15254-E5E8-4A0F-921D-0AA5B3CAF63E

P356

Q34208641-FC4D1644-6547-41D8-8812-A3ACD8587BC8

P433

Q34208641-8316E478-CB83-48FE-9246-C163A51F0658

P478

Q34208641-AD39351F-20DB-430D-813A-1B6DBB5B50BD

P50

Q34208641-CB2C841A-5F5B-410C-9316-C60FD79DBA93

P577

Q34208641-3E3EB7DB-4253-41CB-818B-3C3E2796611B

P698

Q34208641-082F0BB5-2FE8-48E5-B04D-7B0133849745

P921

Q34208641-088F2394-BBCF-4FFB-B56D-B7F7D40F5806

P932

Q34208641-64E6DE6B-EA34-40DF-A106-77698199F053

P356

S1083-8791(03)00228-3

P1433

Biology of Blood and Marrow Transplantation

P1476

Epstein-Barr virus-associated ...... for severe autoimmune diseases

@en

P2093

C Fred Lemaistre

http://www.w3.org/2001/XMLSchema#string

Chien-Shing Chen

http://www.w3.org/2001/XMLSchema#string

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

George E Georges

http://www.w3.org/2001/XMLSchema#string

George H Kraft

http://www.w3.org/2001/XMLSchema#string

James D Bowen

http://www.w3.org/2001/XMLSchema#string

Jan Storek

http://www.w3.org/2001/XMLSchema#string

John Dipersio

http://www.w3.org/2001/XMLSchema#string

Julie Sunderhaus

http://www.w3.org/2001/XMLSchema#string

Kevin T McDonagh

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice.

Epstein-Barr virus lymphoproliferation after bone marrow transplantation.

Early and late interstitial pneumonia following human bone marrow transplantation.

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.

Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies.

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.

Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

P304

583-591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1083-8791(03)00228-3

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Keith M. Sullivan

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14506660

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

2956744

http://www.w3.org/2001/XMLSchema#string